Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of inhaled Trixéo Aerosphere (BGF 160) on tidal breathing complexity in stable COPD
2022-003784-15Phase 4Active
- Sponsor
- CHU de Lille
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of budesonide in chronic obstructive pulmonary disease (COPD), sponsored by CHU de Lille. Primary endpoint: Tidal volume complexity (noise limit). Started Jan 2023; status: active.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2022-003784-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003784-15.